Unknown

Dataset Information

0

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.


ABSTRACT: Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM. We specifically address topics that include the role and timing of an ASCT for MM in the era of novel agents, eligibility for an ASCT, post-ASCT consolidation, and maintenance options, and finally the utility of an upfront tandem ASCT, salvage second ASCT, and an allo-SCT in MM.

SUBMITTER: Gonsalves WI 

PROVIDER: S-EPMC6463224 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves Wilson I WI   Buadi Francis K FK   Ailawadhi Sikander S   Bergsagel P Leif PL   Chanan Khan Asher A AA   Dingli David D   Dispenzieri Angela A   Fonseca Rafael R   Hayman Susan R SR   Kapoor Prashant P   Kourelis Taxiarchis V TV   Lacy Martha Q MQ   Larsen Jeremy T JT   Muchtar Eli E   Reeder Craig B CB   Sher Taimur T   Stewart A Keith AK   Warsame Rahma R   Go Ronald S RS   Kyle Robert A RA   Leung Nelson N   Lin Yi Y   Lust John A JA   Russell Stephen J SJ   Zeldenrust Stephen R SR   Fonder Amie L AL   Hwa Yi L YL   Hobbs Miriam A MA   Mayo Angela A AA   Hogan William J WJ   Rajkumar S Vincent SV   Kumar Shaji K SK   Gertz Morie A MA   Roy Vivek V  

Bone marrow transplantation 20180709 3


Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our  ...[more]

Similar Datasets

| S-EPMC2787395 | biostudies-literature
| S-EPMC5554888 | biostudies-other
| S-EPMC4131249 | biostudies-other
| S-EPMC7359060 | biostudies-literature
| S-EPMC4490016 | biostudies-literature
| S-EPMC5036168 | biostudies-literature
| S-EPMC7990054 | biostudies-literature
| S-EPMC8561280 | biostudies-literature
| S-EPMC2931618 | biostudies-literature
| S-EPMC9378527 | biostudies-literature